RecruitingPhase 4
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Glaukos Corporation · NCT07629557
View Study & Apply (opens in a new tab)
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 13+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 4
- Target enrollment
- 15
- US sites recruiting
- 1
- Study start
- May 11, 2026
- Record last updated
- June 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
Being studied: Riboflavin Ophthalmic Solutions; UV-A Irradiation System
Conditions: Keratoconus
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Provide written informed consent
- Willing and able to comply with study instructions and follow-up visits
- Diagnosis of keratoconus in each eye
Exclusion Criteria
- Known allergy or sensitivity to study medications
- History of corneal disease
- Prior corneal cross-linking in either eye
- Pregnant, nursing, or planning pregnancy during the study period
- Participated in other investigational drug or device trial within 30 days of the study
Recruiting US locations
Glaukos Investigative Site
Westerville, OH 43082
Site contact: Study Director, MD · 949-739-8749 · ClinicalResearch@glaukos.com
Study contacts (from the official record)
- Study Director · 949-739-8749 · ClinicalResearch@glaukos.com